Australia has started the world's first immunotherapy sessions for babies with peanut allergy, a food reaction that could be fatal in some cases. The oral immunotherapy will be started in five states, making it available for the first time in hospitals and ouside of the clinical trials. &nbsp;

Babies aged under 12 months who have peanut allergy can undergo the&nbsp;immunotherapy. Australia's National Allergy Centre of Excellence (NACE) hopes to extend it to more areas if it is effective.

Noting that there has been no widely available treatment for peanut allegey, director &nbsp;of NACE Prof Kirsten Perrett said the new therapy sessons aim "to change the way the most common food allergy in Asustralian children is managed."

Also read:&nbsp;<a href="https://www.wionews.com/science/zombie-viruses-hidden-in-ancient-genes-may-have-accelerated-cancer-study-745570">Zombie viruses hidden in ancient genes may have accelerated cancer: Study</a>

"Ultimately, we want to change the trajectory of allergic disease in Australia so that more children can go to school without the risk of a life-threatening peanut reaction," Australian Broadcasting Corporation quoted Perrett as saying.

<h2>What is peanut allergy immunotherapy?</h2>

The treatment involves giving carefully measured doses of peanut powder to the babies over a period of time.

Also read:&nbsp;<a href="https://www.wionews.com/science/study-shows-strong-links-between-losing-loved-ones-and-ageing-745671">Study shows 'strong links' between losing loved ones and biological ageing</a> 
 
Eventually, the children will reach a "maintenance dose" which can be continued for two years before stopping to see if the treatment has been effective, ABC quoted programme lead Dr Tim Brettig as saying.

<h2>What is peanut allergy?</h2>

One of the most common food allergies, peanut allergy happens when body identifies peanuts or peanut-containing food as harmful and generates an immune reaction.

The allergy symptoms include rashes, vomiting, hives, swelling, sneezing, asthma attack, abdominal pain, drop in blood pressure, diarrhea.

In worst cases, it could lead to cardiac arrests. 
 
(with inputs from agencies) 
&nbsp;

Australia has started the world's first immunotherapy sessions for babies with peanut allergy, a food reaction that could be fatal in some cases. The oral immunotherapy will be started in five states, making it available for the first time in hospitals and ouside of the clinical trials.

Australia has started the world's first immunotherapy sessions for babies with peanut allergy, a food reaction that could be fatal in some cases. The oral immunotherapy will be started in five states, making it available for the first time in hospitals and ouside of the clinical trials. Babies aged under 12 months who have peanut allergy can undergo the immunotherapy. Australia's National Allergy Centre of Excellence (NACE) hopes to extend it to more areas if it is effective. Noting that there has been no widely available treatment for peanut allegey, director of NACE Prof Kirsten Perrett said the new therapy sessons aim "to change the way the most common food allergy in Asustralian children is managed." Also read: Zombie viruses hidden in ancient genes may have accelerated cancer: Study "Ultimately, we want to change the trajectory of allergic disease in Australia so that more children can go to school without the risk of a life-threatening peanut reaction," Australian Broadcasting Corporation quoted Perrett as saying. What is peanut allergy immunotherapy? The treatment involves giving carefully measured doses of peanut powder to the babies over a period of time. Also read: Study shows 'strong links' between losing loved ones and biological ageing Eventually, the children will reach a "maintenance dose" which can be continued for two years before stopping to see if the treatment has been effective, ABC quoted programme lead Dr Tim Brettig as saying. What is peanut allergy? One of the most common food allergies, peanut allergy happens when body identifies peanuts or peanut-containing food as harmful and generates an immune reaction. The allergy symptoms include rashes, vomiting, hives, swelling, sneezing, asthma attack, abdominal pain, drop in blood pressure, diarrhea. In worst cases, it could lead to cardiac arrests. (with inputs from agencies)

World's first immunotherapy for peanut allergy in babies starts in Australia

A wearable patch can now keep&nbsp;severe allergic reaction&nbsp;to peanuts in toddlers at bay,&nbsp;according to the results of a&nbsp;clinical trial.&nbsp;The late-stage trial, which included more than 200 children aged&nbsp;one&nbsp;to three&nbsp;with peanut allergies, found that after applying&nbsp;the experimental patch for over&nbsp;22 hours a day for a year, 67 per cent&nbsp;were able to endure 300 to 1,000 milligrams of peanut protein,&nbsp;the equivalent of one to four peanut kernels.&nbsp;The&nbsp;<a href="https://www.nejm.org/media/doi/full/10.1056/NEJMoa2212895" target="_blank">findings were published</a>&nbsp;in the New England Journal of Medicine.

“Amazingly, not only did it raise the amount of peanut [tolerance] in these children, but the nature of the reaction also changed. There was a decrease in the number of severe reactions,” Dr&nbsp;Matthew Greenhawt, the study’s lead author and director of the Food Challenge and Research Unit at Children’s Hospital Colorado told NBC news.

The patch&nbsp;called Viaskin manufactured by&nbsp;biopharmaceutical firm&nbsp;DBV Technologies, contains a small dose of peanut protein equal to about 1/1,000th of a peanut kernel.

A new patch is applied&nbsp;every day&nbsp;and worn between the shoulder blades so the skin absorbs the protein.

Immune cells then carry the protein to different&nbsp;parts of the body, where they help subdue&nbsp;the allergic response.&nbsp;

There are no approved treatments for children under four&nbsp;with peanut allergies.

However, the Food and Drug Administration has authorised Palforzia, a powder that may be combined with food such as applesauce, yoghurt or pudding, for children aged 4 to 17. Similarly, the powder is intended to reduce the chance of severe allergic responses in children by gradually raising their tolerance to peanuts.

The Viaskin trial, however, is the first to study a non-oral option for the 0-4&nbsp;age category.

According to Dr&nbsp;Pharis Mohideen, chief medical officer of DBV Technologies, the purpose of Viaskin isn't to get children to tolerate peanut-butter-and-jelly sandwiches or to entirely eradicate an allergy.

“We’re trying to build a protective layer for them so that if there is an accidental peanut exposure, they won’t have a reaction, or that reaction will be very mild and not send them to the emergency room,” he told NBC news.

Getting children with peanut allergies to the stage where they can tolerate several peanut kernels, according to Mohideen, is "absolutely life-changing" and would alleviate parents' concerns about taking their children to restaurants or on planes.&nbsp;

“If a label says ‘may contain peanuts,’ but you know you can tolerate a full peanut kernel, the likelihood that that product is safe is pretty high,” he added.

A peanut allergy affects around one in every 50&nbsp;children in the United States. According to a 2018 survey, the frequency of peanut allergies in the country increased over the preceding two decades, although the causes for the development are unclear.

Peanut allergies affect up to 20 per cent&nbsp;of people, while some people's allergies increase over time.

WATCH WION LIVE HERE:

<iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/live-tv/embed" style="width:100%;max-width:560px;" width="560"></iframe>

A wearable patch can now keep severe allergic reaction to peanuts in toddlers at bay, according to the results of a clinical trial. The late-stage trial, which included more than 200 children aged one to three with peanut allergies, found that after applying the experimental patch for over 22 hours a day for a year, 67 per cent were able to endure 300 to 1,000 milligrams of peanut protein, the equivalent of one to four peanut kernels.

A wearable patch can now keep severe allergic reaction to peanuts in toddlers at bay, according to the results of a clinical trial. The late-stage trial, which included more than 200 children aged one to three with peanut allergies, found that after applying the experimental patch for over 22 hours a day for a year, 67 per cent were able to endure 300 to 1,000 milligrams of peanut protein, the equivalent of one to four peanut kernels. The findings were published in the New England Journal of Medicine. “Amazingly, not only did it raise the amount of peanut [tolerance] in these children, but the nature of the reaction also changed. There was a decrease in the number of severe reactions,” Dr Matthew Greenhawt, the study’s lead author and director of the Food Challenge and Research Unit at Children’s Hospital Colorado told NBC news. The patch called Viaskin manufactured by biopharmaceutical firm DBV Technologies, contains a small dose of peanut protein equal to about 1/1,000th of a peanut kernel. A new patch is applied every day and worn between the shoulder blades so the skin absorbs the protein. Immune cells then carry the protein to different parts of the body, where they help subdue the allergic response. There are no approved treatments for children under four with peanut allergies. However, the Food and Drug Administration has authorised Palforzia, a powder that may be combined with food such as applesauce, yoghurt or pudding, for children aged 4 to 17. Similarly, the powder is intended to reduce the chance of severe allergic responses in children by gradually raising their tolerance to peanuts. The Viaskin trial, however, is the first to study a non-oral option for the 0-4 age category. According to Dr Pharis Mohideen, chief medical officer of DBV Technologies, the purpose of Viaskin isn't to get children to tolerate peanut-butter-and-jelly sandwiches or to entirely eradicate an allergy. “We’re trying to build a protective layer for them so that if there is an accidental peanut exposure, they won’t have a reaction, or that reaction will be very mild and not send them to the emergency room,” he told NBC news. Getting children with peanut allergies to the stage where they can tolerate several peanut kernels, according to Mohideen, is "absolutely life-changing" and would alleviate parents' concerns about taking their children to restaurants or on planes. “If a label says ‘may contain peanuts,’ but you know you can tolerate a full peanut kernel, the likelihood that that product is safe is pretty high,” he added. A peanut allergy affects around one in every 50 children in the United States. According to a 2018 survey, the frequency of peanut allergies in the country increased over the preceding two decades, although the causes for the development are unclear. Peanut allergies affect up to 20 per cent of people, while some people's allergies increase over time. WATCH WION LIVE HERE:

In a first, wearable skin patch can now treat peanut allergies in toddlers

UK's National Health Service (NHS) has secured a deal for a new oral treatment that could help hundreds of children in England with peanut allergies. The Independent reported that up to 600 children are expected to be treated this year and 2,000 a year after that will be treated.

England will be the first in Europe to provide the treatment Palforzia, which is an oral immunotherapy, indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts.

This can will give a sigh of relief to the mothers who remain worried that their kids might consume peanuts while they are in school, birthday parties or and eating out and carry adrenaline injections to treat anaphylaxis.&nbsp;

ALSO READ | <a href="https://www.wionews.com/science/scientists-discover-new-muscle-layer-in-human-jaw-that-helps-it-in-stabilisation-439376">Scientists discover new muscle layer in human jaw that helps it in stabilisation</a>

Although, it is advised that self-injectable adrenaline (epinephrine) must be available to the patient at all times. Anaphylaxis is termed a potentially life-threatening allergic reaction.

Palforzia is indicated for the treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy and may be continued in patients 18 years of age and older.

It is important to note that the medicine should be administered under the supervision of a health care professional qualified in the diagnosis and treatment of allergic diseases.

ALSO READ | <a href="https://www.wionews.com/science/covid-australian-researchers-examine-if-blood-thinner-nasal-spray-offers-protection-439152">Covid: Australian researchers examine if blood thinner nasal spray offers protection</a>

Sophie Pratt, the mother of nine-year-old Emily, who took part in the trial, told PA Media that it had "changed our whole family's lives".&nbsp;

"The treatment we received has meant that Emily is free from limits and the fear that the tiniest mistake could put her life at risk, and it has removed all the tension and worry that the simple act of eating loomed over us every day," she said.&nbsp;

NHS medical director Stephen Powis as quoted by The Independent&nbsp;said: "It will reduce the fear and anxiety for patients and their families who may have been living with this allergy for years, and carrying around emergency medication just in case." 
&nbsp;

UK's National Health Service (NHS) has secured a deal for a new oral treatment that could help hundreds of children in England with peanut allergies. The Independent reported that up to 600 children are expected to be treated this year and 2,000 a year after that will be treated.

UK's National Health Service (NHS) has secured a deal for a new oral treatment that could help hundreds of children in England with peanut allergies. The Independent reported that up to 600 children are expected to be treated this year and 2,000 a year after that will be treated. England will be the first in Europe to provide the treatment Palforzia, which is an oral immunotherapy, indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts. This can will give a sigh of relief to the mothers who remain worried that their kids might consume peanuts while they are in school, birthday parties or and eating out and carry adrenaline injections to treat anaphylaxis. ALSO READ | Scientists discover new muscle layer in human jaw that helps it in stabilisation Although, it is advised that self-injectable adrenaline (epinephrine) must be available to the patient at all times. Anaphylaxis is termed a potentially life-threatening allergic reaction. Palforzia is indicated for the treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy and may be continued in patients 18 years of age and older. It is important to note that the medicine should be administered under the supervision of a health care professional qualified in the diagnosis and treatment of allergic diseases. ALSO READ | Covid: Australian researchers examine if blood thinner nasal spray offers protection Sophie Pratt, the mother of nine-year-old Emily, who took part in the trial, told PA Media that it had "changed our whole family's lives". "The treatment we received has meant that Emily is free from limits and the fear that the tiniest mistake could put her life at risk, and it has removed all the tension and worry that the simple act of eating loomed over us every day," she said. NHS medical director Stephen Powis as quoted by The Independent said: "It will reduce the fear and anxiety for patients and their families who may have been living with this allergy for years, and carrying around emergency medication just in case."

Now, children in United Kingdom will get 'life-changing' peanut allergy treatment